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Abstract (300 words) for BMJ open  1 
Objectives: To report the 12 month prevalence of joint bleeds from the national haemophilia 2 
database (NHD) and Haemtrack, a patient-reported online treatment diary; and concurrent 3 
joint disease status using the haemophilia joint health score (HJHS) at individual joint level, in 4 
children and adults with severe haemophilia A and B without a current inhibitor. 5 
Design: A 2018 retrospective database study of NHD from which 2238 cases were identified, 6 
463 patients had fully itemised haemophilia joint health scores (HJHS) of whom 273 were 7 
compliant in recording treatment using Haemtrack. 8 
Setting: England, Wales and Scotland, UK.  9 
Participants: Children (<18y) and adults (≥18y) with severe haemophilia A (HA) and B (HB) 10 
(FVIII/FIX, <0.01 iu/ml) without a current inhibitor. 11 
Primary and secondary outcomes: Prevalence of joint haemarthrosis, and concurrent joint 12 
health measured using the Haemophilia Joint Health Scores (HJHS). 13 
Results: The median (IQR) age of children was 10 (6-13) and adults 40 (29-50) years. 14 
Haemarthrosis prevalence in HA/HB children was 33% and 47%, respectively and 60% and 15 
42%, respectively, in adults. The most common site of haemarthrosis in children was the knee 16 
in HA and ankle in HB. In adults, the incidence of haemarthrosis at the ankles and elbows was 17 
equal. The median total HJHS in HA/HB children was 0 and in adults with HA/HB, were 18 18 
and 11 respectively. In adults with HA/HB, the median ankle HJHS of 4.0 was higher than the 19 
median HJHS of 1.0 for both the knee and elbow. 20 
Conclusion; Despite therapeutic advances, only two-thirds of children and one-third of adults 21 
were bleed-free, even in a UK cohort selected for high compliance with prophylaxis. The 22 
median HJHS of zero in children suggests joint health is relatively unaffected during childhood. 23 
In adults, bleed rates were highest in ankles and elbows, but the ankles led to substantially 24 
worse joint health scores. 25 
4 
 
Strength and limitations of the study (methodology) 1 
• This study reports the 12 month prevalence of haemarthrosis in children and adults 2 
with severe haemophilia without current inhibitors, and associated HJHS as a measure 3 
of joint disease 4 
• Prevalence and site were collated retrospectively from Haemtrack and HJHS from the 5 
National Haemophilia Database 6 
• Only the most compliant of patients who were adherent to taking and reporting 7 
prophylaxis on a national electronic treatment diary Haemtrack with concurrent HJHS 8 
scores were included 9 
• Sample size was affected by methodology including those with electronic fully itemised 10 
HJHS and above 75% threshold of compliance. 11 
•  The design of this study does not allow examination of longitudinal joint bleed or joint 12 





Haemophilia is a rare x-linked recessive genetic disorder characterised by bleeding into soft 2 
tissue and joints [1]. The most common forms are haemophilia A and B, affecting 1:10000 and 3 
between 1:35,000 and 1:50,000 respectively. The disease is further characterised by the 4 
levels of factor VIII (FVIII) and factor VIX (FVIX), with the most severely affected having less 5 
than 1% (<0.01 IU/mL) circulating clotting factor (severe haemophilia) [2]. Musculoskeletal 6 
bleeding is the most common haemorrhagic manifestation, with 90% of bleeds occurring in 7 
muscles or joints [1]. The presence of blood products within the joint space and the process 8 
of removal leads to synovial hypertrophy, haemosiderin deposition and eventually arthropathic 9 
joint changes [3]. Over time, repeated haemarthrosis results in chronic synovitis, changes in 10 
cartilage and bone composition and progressive chronic haemarthropathy [4, 5]. 11 
Infusion of replacement clotting factor concentrates (CFC) is prescribed with the aim of 12 
elevating circulating factor to a level that halts spontaneous and traumatic bleeding [1]. CFC 13 
treatment is not without complication. The development of anti-Factor antibodies or “inhibitors” 14 
in some people produces an immune response to CFC infusion that significantly reduces the 15 
effectiveness of CFC treatment. Development of inhibitors increase the risk of bleeding, joint 16 
damage and requirement for factor treatment bypassing agents [6]. Ultimately the aim of 17 
modern treatment of haemophilia is prevention of joint bleeds with a target of achieving zero 18 
bleeds whenever possible. Prevention of haemarthrosis in all age groups is important and in 19 
particular in children, where musculoskeletal immaturity exposes joints to greater risk of 20 
damage in later life. Multiple studies have shown that early initiation of CFC prophylaxis in 21 
children delays joint damage and reduces joint disease [7-10]. In adults, multi-joint 22 
haemarthropathy remains a common feature of the disease, but even prophylaxis started in 23 
adulthood decreases bleeding, improves pain and improves health related quality of life 24 
(HRQoL) [11]. Therefore in children and adults prophylaxis is considered the standard of care 25 
for all patients [11, 12]. Traditionally, prophylactic treatment in severe haemophilia aims to 26 
maintain Factor VIII (FVIII) or Factor IX (FIX) at a trough level >0.01 iu/ml. It is apparent that 27 
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many patients experience spontaneous as well as traumatic bleeds, despite achieving trough 1 
Factor levels > 0.01 iu/ml. Several approaches have been adopted or are being investigated 2 
with the aim of attaining complete bleed avoidance, including more individualised treatment 3 
with standard half-life products, the use of coagulation factors with extended half-lives, and 4 
innovative non-Factor treatments [12-15].  5 
Recent evaluation of real world treatment regimes in severe and moderate haemophilia in the 6 
UK and Europe, has shown that despite adequate coagulation factor concentrate availability, 7 
treatment is still suboptimal. In 2015, data from the United Kingdom National Haemophilia 8 
Database (NHD) reported median (IQR) annualised bleed rates (ABR)/ annualised joint bleed 9 
rates (AJBR) in children (0-11y) and adolescents (12-18y) of 1.0 (0.0-0.5)/ 0.0 (0.0-1.0) and 10 
2.0 (0.0-7.0)/ 1.0 (0.0-3.0), respectively. ABR in adults with severe haemophilia A on 11 
prophylaxis were 2.0 (IQR 0.0-7.0) and AJBR was 1.0 (IQR 0.0-4.0) with only 29% bleed free 12 
and 34% joint bleed free [16]. Similarly, reported European (Belgium, France, Germany, Italy, 13 
Spain, Sweden, and UK) data shows median AJBR of 1.0 – 4.0. [16, 17]. However, data on 14 
bleeding frequency and severity of haemarthropathy at an individual joint level is lacking.  15 
The main sites of haemarthrosis are the elbows, ankles and the knees, with the shoulders, 16 
wrists and hips less commonly affected and data for these sites not collated by the NHD. The 17 
haemophilia joint health score (HJHS) is a standardised clinical assessment tool developed to 18 
assess upper and lower limb joint health status. The clinical assessments undertaken by 19 
specialist physiotherapists at 6-12 month intervals include measurement of swelling, 20 
alignment, range of motion, and muscle atrophy, and forms part of the UKHCDO haemophilia 21 
management guidelines [18, 19]. The HJHS is the most widely used score of joint health in 22 
haemophilia and has shown good to moderate correlations with radiological scores of joint 23 
disease using the Pettersson score [18]. However haemarthrosis is not reported by the HJHS 24 
and therefore incidence of haemarthrosis and joint disease at an individual joint level are 25 
unknown [20].   26 
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Those deemed most compliant with prophylaxis are less likely to experience repeated 1 
incidents of haemarthrosis and therefore less likely to have established joint disease when 2 
compared to those who do not adhere to treatment. This may be a smaller proportion than 3 
those who do not adhere to treatment but these cases are important in gauging the efficacy 4 
of current treatments [11, 19, 20]. Understanding prevalence and joint disease in the most 5 
compliant of patients may provide direction for future research of patient compliance and 6 
management of joint disease, including non-pharmacological interventions and intra-articular 7 
therapies commonly used in the management of MSK conditions. 8 
 9 
Objective 10 
The primary objective of this study is to determine the prevalence and incidence of joint 11 
bleeding and joint disease using the HJHS at an individual joint level in children and adults 12 
with severe haemophilia A and B without a current inhibitor. 13 




Ethical approval was obtained on 24th January 2017 (IRAS: 206141, R&D: PD16/227) 2 
Approval to access data from the UKHCDO NHD Data Analysis Group was granted on 12th 3 
July 2019 and the analysis report produced by UKHCDO on the 4th October 2019. The study 4 
has been reported in accordance with the UKHCDO NHD guidelines and regulations.  5 
Data on bleed prevalence and site were collated retrospectively from the Haemtrack patient 6 
therapy recording system and the clinical Haemophilia Joint Health Score from the National 7 
Haemophilia Database. Haemtrack is a UK national online treatment diary in which individual 8 
patients regularly report details of treatments with coagulation factor concentrates (CFC) [20, 9 
21]. Details of home delivery of CFC treatment to patients is recorded by the corresponding 10 
haemophilia treatment centre and then uploaded to the NHD. When CFC is administered by 11 
the patient that individual treatment is then recorded on Haemtrack, including the reason for 12 
each treatment such as prophylaxis or bleed treatment and the site of each bleed. Data 13 
recorded in Haemtrack are then integrated with NHD [20]. The 2018-2019 UKHCDO report 14 
indicated median compliance at haemophilia comprehensive care centres (CCC) and 15 
haemophilia treatment centres (HC) of 90% and 93% respectively with the NHD definition of 16 
compliance recorded use of ≥75% of received factor concentrate [22].  The HJHS Version 2.1 17 
is collated as six individual joint scores (0-20) and compiled with a global gait score (0-4) to a 18 
total score (0-124). A higher HJHS score represents worse joint health.  19 
Participants were children (<18 years old) and adults (≥18 years old) with severe haemophilia 20 
A and B (FVIII or FIX <0.01 IU/mL) without a current inhibitor, who had been issued with 21 
coagulation factor concentrates in the UK between 1st January and 31st December 2018. 22 
Regular prophylaxis was defined for those using standard half-life (SHL) prophylaxis as >=2 23 
infusions per week for Haemophilia A, and >=1 infusions/week for haemophilia B for >45 24 
weeks/year; for patients using extended half-life (EHL) products, >=1 infusions/week for 25 
haemophilia A, and more than once every two weeks for haemophilia B for >45 weeks/year. 26 
Low dose prophylaxis is not prescribed in the UK, therefore, prophylaxis was assumed as 27 
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above 25 IU/kg to maintain a trough level above 0.02 IU/ml [23]. Those included in the analysis 1 
were Haemtrack compliant (defined as recorded use of ≥75% of received factor concentrate) 2 
with a corresponding electronically recorded Haemophilia Joint Health Score (HJHS) Version 3 
2.1. 4 
The joint bleed prevalence (%) for paediatric and adult patients and AJBR and HJHS were 5 
collated from Haemtrack and NHD. AJBR were reported by patients through the Haemtrack 6 
and recorded over the 12 month study period (1st January to 31st December 2018). Adequate 7 
primary and secondary prophylaxis and adherence to treatment are known to reduce bleed 8 
rates and reduce the burden of joint disease [11, 19]. Therefore only data from the most 9 
compliant patients (≥75% received factor concentrate vs recorded in Haemtrack) were 10 
reported as per the NHD standard operating procedure for data analysis and reporting. Joint 11 
bleed prevalence, AJBR and HJHS are reported for all joints (total) and in each individual joint. 12 
Data are summarised using means and standard deviations (SD) or medians and interquartile 13 
ranges (IQR, 25; 75 percentiles). 14 
 15 
Patient and Public Involvement: Patients from the Leeds Haemophilia Comprehensive Care 16 
Centre, Leeds, UK and The NIHR Leeds Biomedical Research Centre (BRC), Leeds, UK were 17 
involved in the original design of the author’s clinical doctoral research fellowship and this 18 





During 2018, 2238 individuals with severe haemophilia A (n=1889) and B (n=349) without a 2 
current inhibitor were registered with the NHD and 1396 were registered with Haemtrack.  3 
Electronically recorded fully itemised HJHS data was available for 463 patients with 4 
contemporaneous Haemtrack available for 273 individuals of whom 86.8% (n=237) had 5 
haemophilia A and 13.2% (n=36) haemophilia B. Participant age and treatment characteristics 6 
are presented in Table 1. 7 
Table 1: Participant characteristics 8 
Patient 
characteristics 
Haemophilia A Haemophilia B 
Age < 18 (n=80) 
Age ≥ 18 (n=157) Age < 18 (n=17) Age ≥ 18 (n=19) 
Age (median, IQR) 10 (7; 13) 40 (29; 50) 12 (7;14) 45 (25; 48) 
SHL 67% (n=54) 77% (n=121) 18% (n=3) 32% (n=6) 
EHL 29% (n=23) 23% (n=36) 70% (n=12) 42% (n=8) 
SHL-EHL 4% (n=3) 0% 12% (n=2) 26% (n=5) 
SHL= Standard Half-life product, EHL= Extended Half-life product, SHL-EHL=switch from a SHL to a EHL during the 12 month study period.  9 
 10 
Joint bleed prevalence and annual bleed rate 11 
Joint bleed prevalence (%) and individual joint prevalence, and total AJBR are presented in 12 
Table 2. Bleed data are categorised by age, haemophilia type (A and B) and the most 13 
commonly effect joints (left and right) of the elbows, knees and ankles. Joint bleed prevalence 14 
in children with haemophilia A (32.5%) and haemophilia B (47.1%) reported at least one 15 
incidence of joint bleeding over the 12 month study period. Adults with haemophilia A (59.9%) 16 
and B (42.1%) reported at least one bleed over the same time period. Median AJBR at 17 
individual joints for children and adults were 0.0 (0.0;0.0) with the exception of the left ankle 18 
in children with haemophilia B (0.0;1.0). Mean AJBR for adults and children at the ankles, 19 





Figure 1: Combined annual joint bleed rate for children (vertical and horizontal black 1 
columns) and adults (solid grey and black columns) with severe haemophilia A and B.  2 
  3 
12 
 
Table 2. Annual joint bleed prevalence and AJBR of children and adults 1 
Annual Joint Bleed Prevalence  Haemophilia A Haemophilia B 
 
Age < 18 (n=80) Age ≥ 18 (n=157) Age < 18 (n=17) Age ≥ 18 (n=19) 
Annual Joint Bleed Rate All joints Median (IQR) 
0.0 (0.0;1.0) 1.0 (0.0;4.4) 0.0 (0.0;2.0) 0.0 (0.0;3.5) 
Joint Bleed Prevalence 
All joints n (%) 
26 (32.5) 94 (59.9) 8 (47.1) 8 (42.1) 
Right Ankle n (%) 
2 (2.5) 27 (17.2) 1 (5.9) 2 (10.5) 
Left ankle n (%) 
5 (6.3) 35 (22.3) 5 (29.4) 2 (10.5) 
Right knee n (%) 
13 (16.3) 27 (17.2) 1 (5.9) 2 (10.5) 
Left knee n (%) 
7 (8.8) 24 (15.3) 1 (5.9) 2 (10.5) 
Right elbow n (%) 
6 (8.0) 29 (18.5) 1 (5.9) 3 (15.8) 
Left elbow n (%) 
4 (5.0) 35 (22.3) 1 (5.9) 2 (10.5) 
Joint bleed prevalence (%): Numerator = number of patients who had bleeds, Denominator = total cohort number,  2 
  3 
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Haemophilia joint health score 1 
HJHS categorised by age, haemophilia type and joint are presented in Table 3. Median (IQR) 2 
of HJHS in children were 0.0 (0.0; 0.0) in both haemophilia A and B. In adults the total HJHS 3 
were higher than in children; the total HJHS is higher in haemophilia A than haemophilia B. At 4 
an individual joint level median (IQR) ankle HJHS of 4.0 (0.0; 8.0) were higher than for the 5 
knee 2.9 (4.1)/ 1.00 (0.0; 5.0) and elbow 3.3 (4.1)/ 1.0 (0.0; 7.0). 6 
Table 3. Haemophilia joint health scores for children and adults  7 
Haemophilia joint health scores Haemophilia A Haemophilia B 
Median (IQR) Age < 18 (n=80) Age ≥ 18 (n=157) Age < 18 (n=17) Age ≥ 18 (n=19) 
All Joints 0.0 (0.0;0.0) 18.0 (6.0;31.0) 0.0 (0.0;0.0) 11.0 (5.0;24.0) 
Right ankle 0.0 (0.0;0.0) 4.0 (0.0;8.0) 0.0 (0.0;0.0) 2.0 (0.0;7.0) 
Left ankle 0.0 (0.0;0.0) 4.0 (0.0;8.0) 0.0 (0.0;0.0) 4.0 (1.0;8.0) 
Right knee 0.0 (0.0;0.0) 1.0 (0.0;4.0) 0.0 (0.0;0.0) 0.0 (0.0;1.0) 
Left knee 0.0 (0.0;0.0) 1.00 (0.0;5.0) 0.0 (0.0;0.0) 0.0 (0.0;2.0) 
Right elbow 0.0 (0.0;0.0) 1.0 (0.0;7.0) 0.0 (0.0;0.0) 0.0 (0.0;1.0) 
Left elbow 0.0 (0.0;0.0) 1.0 (0.0;6.0) 0.0 (0.0;0.0) 0.0 (0.0;1.0) 
HJHS: Global Gait score not included 8 




In this study we report the current prevalence of haemarthrosis in children and adults with 2 
severe haemophilia without current inhibitors, and associated HJHS as a measure of joint 3 
disease. The study was conducted retrospectively, using data from 2018 in a national 4 
database. In a national cohort of 2338 individuals, 463 patients had electronically-recorded 5 
fully itemised HJHS, with the sample size further reduced to 273 patients who met the fully 6 
Haemtrack compliant criteria. During the data collection period, 62% of the national cohort 7 
used Haemtrack, 20% of whom fulfilled compliance criteria set by the NHD, permitting analysis 8 
of haemarthrosis and joint health status of a representative sample of UK with severe 9 
haemophilia without inhibitors. The sample size whilst small is focused only the most compliant 10 
of patients and provides insight to the current compliance rates and reporting of joint diseases 11 
to the NHD. The results presented in this paper represent the likely best case scenario for the 12 
most complaint cases and this further highlight the 80% of patients who fail to either record or 13 
comply with treatment and raises questions as to the real compliance and adherence to 14 
treatment, as well as the concurrent joint disease in patients who do not meet the 75% NHD 15 
inclusion threshold. 16 
In children with severe haemophilia, average AJBR were low across haemophilia types. One 17 
in three children did however experience a joint bleed during the 12 month data collection 18 
period. The majority of those included would have typically been provided prophylaxis from an 19 
early age and continue to adhere to a prophylaxis regime, but 30% of children still experienced 20 
haemarthrosis during the 12 month data collection period. HJHS itemised by joint were very 21 
low in children (Table 3) suggesting either minimal joint disease or that the HJHS might not 22 
be sensitive to early joint changes following haemarthrosis. Reliability of the HJHS has been 23 
explored in children and young adults and is reported to be sensitive to early joint changes  24 
[24, 25] , although individual joint HJHS of less than three at the knee and ankle are less able 25 
to identify pathological joint change when compared to MRI and US imaging [18]. Similarly in 26 
children, correlations between the HJHS and the Haemophilia Early Arthropathy Detection 27 
15 
 
with UltraSound (HEAD-US) have shown good correlations in the identification of joint 1 
pathology at the elbows and knees, however at the ankles significant difference are reported 2 
between HJHS and HEAD-US scores with underreporting of ankle joint pathology in both 3 
instances [26]. Therefore a combined approach to joint health assessment may identify 4 
pathology especially at the ankle joint prior to the progression to haemarthropathy. Canine, 5 
mouse and human in-vitro models have demonstrated chondrocyte apoptosis and reduced 6 
proteoglycan synthesis affecting cartilage matrix turnover within 48-96 hours of an induced 7 
joint bleed, suggesting a single joint bleed may have detrimental effects on joint cartilage [27-8 
29]. Formally reported bleed rates in the NHD are relatively low, however micro bleeding 9 
(subclinical bleeding not clinically detectable, or experienced by the patient) is an emerging 10 
theme in haemophilia. Episodes of subclinical bleeding may contribute to the deterioration of 11 
joint health despite no clinically detectable signs of a joint bleed, therefore point of care 12 
ultrasound tools such as the HEAD-US may provide early evidence of joint disease [3]. 13 
In the adult population, AJBR were higher than those reported in children, with mean (SD) 14 
AJBR of 3.9 (7.0) and median (IQR) 1.0 (0.0-4.4) in haemophilia A and 2.0 (3.6) and 0.0 (0.0-15 
3.5) in haemophilia B, respectively. The 12 month prevalence was also higher, with 60% and 16 
41% of adults with haemophilia A and B, respectively, experiencing at least one bleed over 17 
the period. HJHS scores at the ankle joint were similar to the elbows, with knees slightly less 18 
affected. Interestingly the median scores at both the knee and elbow were lower than that of 19 
the ankle, suggesting that there is worse ankle joint health overall when compared to other 20 
joints. Ankle joint changes are driven by the mechanical demand on the ankle and forces 21 
exerted on the joint during activities of daily living, in combination with structural and functional 22 
changes often seen in adolescents and adults with severe haemophilia [30, 31]. Our data 23 
suggest that very early signs of joint disease might not be detected by the HJHS; rather it 24 
measures the cumulative effect of haemarthropathy, not detectable until later years. 25 
AJBR in this study are slightly lower (Table 2) than those reported in the UK THUNDER study 26 
conducted three years earlier using the same NHD database [11]. Scott et al. reported a 27 
16 
 
median AJBR of 0.0 in children (0-11 years), 1.0 in adolescents (12-18 years) and 3.0 in adults 1 
aged 19 and above. Our prevalence data (Table 1) for both children and adults indicate a 2 
slight decrease AJBR since the Scott et al. study [16]. In terms of the treatment profile of those 3 
included in our study, about one quarter were now using an EHL product and 96% of those 4 
sampled are receiving and are compliant with treatment. In addition Scott et al did not include 5 
those patients with haemophilia B who are reported to have better joint health and less 6 
frequent joint bleeds [32].  A longitudinal evaluation of tailored frequency-escalated 7 
prophylaxis in a Canadian cohort of children aged 1.0 - 2.5 years (n=36) followed up over 10.2 8 
years (IQR 8.5-13.6) reported median index annual haemarthrosis rates of 0·95 (0·44–1·35) 9 
which is similar to our own results. Prophylaxis treatment in Canada was driven by bleed 10 
incidence and escalated accordingly, so their treatment was more targeted and reactive [33]. 11 
The Canadian study shows that avoidance of all joint bleeding is unlikely to be possible, and 12 
in our own cohort the mean (SD) AJBR of 0.81 (1.68) and 1.00 (1.18) in haemophilia A and B 13 
children respectively, indicate that bleeding is occurring in some children even when compliant 14 
with prophylaxis. In a Dutch study of haemophiliac adults (n=62) over a 5-10 year period with 15 
a low median AJBR (IQR) 0.0 (0.0-2.0) there was still a worsening of joint health, with a HJHS 16 
increase of more than 4 points over the study period in 37.1% of patients, and with the ankle 17 
joints most often affected (30.6%)  [34]. Those adults sampled in this study still had up to four 18 
joint bleeds over a 12 month period, with 60% of all adults reporting a minimum of one joint 19 
bleed. Forty percent of individuals sampled reported no bleeds and were well controlled, but 20 
for the remaining 60% it is unclear why joint bleeding occurred. Understanding why the 60% 21 
in this cohort reported haemarthrosis may lead to better targeted and individualised treatment 22 
and identification of other contributing factors such as lifestyle and altered, combined and 23 
individual joint biomechanics of the upper and lower limbs. 24 
A limitation of this study is the low proportion of patients registered on the UK database that 25 
had full Haemtrack and itemised HJHS data recorded at the time of data collection. The NHD 26 
does not report bleed level data on patients who do not use Haemtrack owing to the difficulty 27 
17 
 
in collecting data from paper diaries and established links at each haemophilia centre through 1 
the NHD Haemophilia Centre Information System (HCIS), limiting analysis to Haemtrack 2 
compliant users [20]. Bias may have been introduced by the study design through the inability 3 
to include those not recording treatment in Haemtrack and those for whom HJHS examinations 4 
were not reported or itemised by joint to the NHD. Although this is the largest reported dataset 5 
of HJHS, the lack of linkage between elements of the data limits its wider utility. As electronic 6 
reporting of HJHS to the NHD becomes more routine and the dataset expands, we will be able 7 
link HJHS and joint health to rates of haemarthrosis. Haemtrack data compliance is defined 8 
as  ≥75% of home delivery treatment received being recorded as used by the patient and so 9 
those who met the inclusion criteria are regarded as “good reporters” and deemed likely to be 10 
compliant with treatment [20]. The current bleeding and joint disease profiles of those who 11 
receive and record treatment, but fall below the 75% treatment adherence criteria is unknown.  12 
Access to individual treatment dose and trough levels were not available from the database 13 
and is acknowledged as a limitation of this study. Reporting of these data relies on haemophilia 14 
centres uploading real time data, including trough levels and up to date measurements of 15 
weight but requires access to patient’s data and requires better reporting methods to be 16 
achievable. Understanding joint haemarthrosis in this subset of patients may provide further 17 
insight into the real-world prevalence of haemarthrosis. This study focusses, for databasing 18 
reasons, on the most compliant cases and therefore those within the broader haemophilia 19 
population likely to be suffering the fewest consequences. It might be reasonable to expect 20 
that over the 12 month study period, comparable patients who do not report or full comply with 21 
treatment may have had higher bleed rates. Consequently it would also be expected that joint 22 
health may also be worse or deteriorating at a faster rate. Compliance is important because it 23 
represents a gap between the availability of best treatment and impact of treatment on the 24 
consequences. Less compliant patients may require different behavioural or system-based 25 
approaches to encourage compliance and better reporting and monitoring.    26 
18 
 
As expected due to the lower prevalence, the sample of haemophilia B patients in this analysis 1 
is smaller than the haemophilia A cohort, and therefore differences in joint bleed prevalence 2 
and HJHS between patients with haemophilia A and B should be interpreted with caution. 3 
Those with haemophilia B may present with a milder bleeding phenotype than that of 4 
haemophilia A regardless of severity or treatment [32, 35, 36]. In addition people with 5 
haemophilia B may display less severe levels of haemarthropathy, with differences in the 6 
specific pathophysiological mechanisms of joint disease underlined by different rates of joint 7 
deterioration and severity [37]. Direct comparison between disease types is limited and 8 
therefore further research is needed to explore whether the lower bleed rates and better joint 9 
health in people with haemophilia B suggested in this study can be confirmed. 10 
History of spontaneous and traumatic bleeding could not be separated, owing to data reporting 11 
methods within Haemtrack. Whilst prophylaxis protects against spontaneous bleeding there is 12 
still a proportion of these treatment compliant adults reporting up to four joint bleeds in the 12 13 
month study period. Haemarthrosis may occur as individual joint events, but our data 14 
highlights the burden on overall joint disease. A previous history of developing inhibitors and 15 
a history of on-demand treatment now using secondary prophylaxis may predispose patients 16 
to higher levels of joint disease and greater risk of subsequent haemarthrosis [11]. Further 17 
research is required therefore to understand the bleeding profile and burden of disease in 18 
adults with established joint disease and previous inhibitor status. 19 
A further limitation is between-centre variability in HJHS assessment [38]. HJHS data from 20 
different haemophilia centres may be subject to inter-centre scoring variability, although 21 
workshops have been conducted in the UK to decrease inter‐centre variability in HJHS 22 
scoring. Furthermore, we are unable to confirm the influence of other factors such as the 23 
presence of co‐morbid musculoskeletal conditions on HJHS data. UKHCDO NHD data was 24 
also requested from those with moderate disease but there was insufficient data to include in 25 
the analysis. Future comparison by disease severity (severe and moderate) may provide 26 





Clinical implication and conclusion: 3 
In a UK cohort of Haemtrack compliant patients with severe haemophilia and without a current 4 
inhibitor, only 70% of children and 30% of adults remained haemarthrosis free during 2018. 5 
Haemarthrosis was most likely to be reported in the knee joint in children with haemophilia A, 6 
the ankle joint in children with haemophilia B, the elbow and ankle joint in adults with 7 
haemophilia A, and the elbow joint in adults with haemophilia B. Overall higher HJHS were 8 
reported for the ankle joint compared to the knee and elbow, suggesting that the ankle joint is 9 
the most severely compromised joint in people with haemophilia. 10 
Investigation of impact on function and potential interventions that lessen the burden of 11 
disease are warranted. Future clinical studies would also benefit from understanding the 12 
bleeding profiles of those who do not meet compliance criteria for Haemtrack or other 13 
database-linked bleed data to obtain the true prevalence of haemarthrosis and joint disease.  14 
 15 




ABR: Annual bleed rate 2 
AJBR: Annual joint bleed rate 3 
CFC: Clotting factor concentrate 4 
EHL: Extended half life  5 
HJHS: Haemophilia joint health score 6 
NHD: National Haemophilia Database 7 
SHL: Standard half-life 8 
UKHCDO: United Kingdom Haemophilia Doctors Organisation 9 
  10 
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